Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2010 - 2026)

Lineage Cell Therapeutics' Other Non Operating Income history runs 17 years deep, the most recent figure standing at $1000.0 for Q1 2026.

• In Q1 2026, Other Non Operating Income rose 100.43% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $232000.0 (up 136.94% YoY), while the FY2023 annual figure was $542000.0, up 125.19% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $1000.0, up from -$1.7 million in the prior quarter.
• The five-year high for Other Non Operating Income was $1.7 million in Q2 2025, with the low at -$1.9 million in Q2 2022.
• The 5-year median for Other Non Operating Income is -$101500.0 (2022), against an average of -$184000.0.
• Peak annual rise in Other Non Operating Income reached 543.92% in 2025, while the deepest fall reached 8668.42% in 2025.
• Lineage Cell Therapeutics' Other Non Operating Income stood at $398000.0 in 2022, then tumbled by 100.5% to -$2000.0 in 2023, then plunged by 850.0% to -$19000.0 in 2024, then plunged by 8668.42% to -$1.7 million in 2025, then jumped by 100.06% to $1000.0 in 2026.
• Business Quant data shows LCTX's Other Non Operating Income at $1000.0 in Q1 2026, -$1.7 million in Q4 2025, and $219000.0 in Q3 2025.